Effect of p21(WAF1/CIP1) expression on tumor progression in bladder cancer

Journal of the National Cancer Institute

Volumn 90, Issue 14, 1998, Pages 1072-1079

  Stein, John P ^a   Ginsberg, David A ^a   Grossfeld, Gary D ^a   Chatterjee, Sunanda J ^a   Esrig, David ^a   Dickinson, Ming G ^a   Groshen, Susan ^a   Taylor, Clive R ^a   Jones, Peter A ^a   Skinner, Donald G ^a   Cote, Richard J ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P21; PROTEIN P53; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER SURVIVAL; CELL CYCLE S PHASE; CYSTECTOMY; DISEASE COURSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR RECURRENCE; BLADDER TUMOR; CANCER STAGING; CHEMISTRY; GENE EXPRESSION REGULATION; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; RISK; SURVIVAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYSTECTOMY; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RISK; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0032527133     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.14.1072     Document Type: Article

References (35)

1. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-64.
2. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993;85:53-9.
3. Lane DP. Cancer. p53, guardian of the genome [news]. Nature 1992;358: 15-6.
4. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, et al. Mice deficient for p53 are developmemally normal but susceptible to spontaneous tumours. Nature 1992;356:215-21.
5. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-4.
6. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
7. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995;147:545-60.
8. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75: 817-25.
9. 1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
10. Buchkovich K, Duffy LA, Harlow E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 1989;58:1097-105.
11. Loda M, Cukor B, Tam SW, Lavin P, Fiorentine M, Draetta GT, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3: 231-4.
12. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-30.
13. Porter P, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, et al. Expression of cell cycle regulators p27Kip1 and cyclin E, alone or in combination, correlate with survival in young breast cancer patients. Nat Med 1996;3:222-5.
14. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
15. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994;54: 3391-5.
16. Bond JA, Blaydcs JP, Rowson J, Haughton MF, Smith JR, WynfordThomas D, et al. Mutant p53 rescues human diploid cells from senescence without inhibiting the induction of SDI1/WAF1. Cancer Res 1995;55: 2404-9.
17. Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, et al. p53-independent expression of p21Cip1 in muscle and other terminal differentiating cells. Science 1995;267:1024-7.
18. Zhang W, Grasso L, McClain CD, Gambel AM, Cha Y, Travali S, et al. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res 1995;55:668-74.
19. Bergkvist A, Ljungqvist A, Moberger G. Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of eight years. Acta Chir Scand 1965;130:371-8.
20. Hermanek P, Sobin LH, eds. TMN classification of malignant tumors. 4th ed. New York: Springer-Verlag/1992;154-6.
21. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffinembedded tissues; an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741-8.
22. Gudas J, Nguyen H, Li T, Hill D, Cowan KH. Effects of cell cycle, wild-type p53 and DNA damage on p21CIP1/Waf1 expression in human breast epithelial cells. Oncogene 1995;11:253-61.
23. Munty VN. Binomial and poisson probabilities with an HP-285 scientific advanced calculator. J Appl Stat 1990;17:411-4.
24. Fienberg SE. The analysis of cross-classified categorical data. Cambridge, (MA): MIT Press, 1977:9-86.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1955;53:457-81.
26. Miller RG Jr. Survival analysis. New York: John Wiley & Sons, 1981: 44-102.
27. Gaynor JJ, Feuer EJ, Tan CC, et al. On the use of cause-specific failure and conditional failure probabilities: example from clinical oncology data. J Arn Stat Assoc 1993;88:400-9.
28. Greenhalgh DA, Wang XJ, Donehower LA, Roop DP. Paradoxical tumor inhibition effect of p53 loss in transgenic mice expressing epidermaltargeted v-rasHa, v-fos, or human transforming growth factor alpha. Cancer Res 1996;56:4413-23.
29. Fearon ER, Vogelstein B. A genetic model for colorectal tumorgenesis. Cell 1990;61:759-67.
30. Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi SR, Tran QC, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998;58:1090-4.
31. Cordon-Cardo C, Zhang ZF, Dalbagni G, Drobnjak M, Charytonowicz E, Hu SX, et al. Cooperative effects of p53 and pRb alterations in primary superficial bladder tumors. Cancer Res 1997;57:1217-21.
32. Shapiro GI, Edwards CD, Kobzik L, Godleski J, Richards W, Sugarbaker DJ, et al. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 1995;55:505-9.
33. Kratzke RA, Greatens TM, Rubins JB, Maddaus MA, Niewoehner DE, Niehans GA, et al. Rb and p16INK4 expression in resected non-small cell lung tumors. Cancer Res 1996;56:3414-20.
34. Lacombe L, Orlow I, Silver D, Gerald WL, Fair WR, Reuter VE, et al. Analysis of p21WAF1/CIP1 in primary bladder tumors. Oncology Res 1996;8:409-14.
35. Malkowicz SB, Tomasezewski JE, Linnenbach AJ, Cangiano TA, Maruta Y, McGarvey TW. Novel p21WAF1/CIP1 mutations in superficial and invasive transitional cell carcinomas. Oncogene 1996;13:1831-7.